Insider trading

Period: 120 months Stock: BDTX Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

28 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

28 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

28 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

28 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
28 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
28 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

28 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
27 Jun 2023
Epstein David M. SEE REMARKS
Sold on a plan
$167.50K 25,000 at 6.70
3.6%
Planned (10b5-1)
22 Dec 2022
Ni Fang SEE REMARKS
Bought
$46.60K 36,363 at 1.28
40.8%
+41% of stake
21 Dec 2022
Ni Fang SEE REMARKS
Bought
$25.77K 20,000 at 1.29
29.0%
+29% of stake
29 Jun 2022
Ni Fang SEE REMARKS
Bought
$61.02K 25,000 at 2.44
56.8%
First buy on file
12 May 2021
Hatzis-Schoch Brent See Remarks
Sold, plan not stated 3×
$111.80K 4,078 at 27.42
32.7%
3 May 2021
Roberts Christopher D. Chief Scientific Officer
Sold, plan not stated
$66.60K 2,500 at 26.64
43.9%
12 Apr 2021
Hatzis-Schoch Brent See Remarks
Sold, plan not stated
$101.95K 4,078 at 25.00
32.7%
5 Apr 2021
Roberts Christopher D. Chief Scientific Officer
Sold, plan not stated
$63.85K 2,500 at 25.54
43.9%
12 Mar 2021
Hatzis-Schoch Brent See Remarks
Sold, plan not stated
$107.49K 4,078 at 26.36
32.7%
3 Mar 2021
Roberts Christopher D. Chief Scientific Officer
Sold, plan not stated 2×
$65.26K 2,500 at 26.10
43.9%
12 Feb 2021
Hatzis-Schoch Brent See Remarks
Sold, plan not stated 2×
$111.02K 4,078 at 27.23
32.7%
3 Feb 2021
Roberts Christopher D. Chief Scientific Officer
Sold, plan not stated
$63.38K 2,500 at 25.35
43.9%
12 Jan 2021
Hatzis-Schoch Brent See Remarks
Sold, plan not stated 6×
$394.04K 11,578 at 34.03
58.0%
Sold half or more
4 Jan 2021
Epstein David M. See Remarks
Sold, plan not stated 2×
$373.50K 12,000 at 31.13
1.7%
4 Jan 2021
Roberts Christopher D. Chief Scientific Officer
Sold, plan not stated 2×
$78.52K 2,500 at 31.41
43.9%
14 Dec 2020
Hatzis-Schoch Brent See Remarks
Sold, plan not stated
$142.52K 4,078 at 34.95
57.6%
Sold half or more
3 Dec 2020
Roberts Christopher D. Chief Scientific Officer
Sold, plan not stated
$81.06K 2,500 at 32.42
100%
Sold half or more
1 Dec 2020
Epstein David M. See Remarks
Sold, plan not stated 2×
$392.57K 12,000 at 32.71
1.7%
12 Nov 2020
Hatzis-Schoch Brent See Remarks
Sold, plan not stated 3×
$138.61K 4,078 at 33.99
57.6%
Sold half or more
11 Nov 2020
Roberts Christopher D. Chief Scientific Officer
Sold, plan not stated
$174.50K 5,000 at 34.90
100%
Sold half or more
3 Nov 2020
Roberts Christopher D. Chief Scientific Officer
Sold, plan not stated
$79.87K 2,500 at 31.95
100%
Sold half or more
2 Nov 2020
Epstein David M. See Remarks
Sold, plan not stated 2×
$373.66K 12,000 at 31.14
1.7%
12 Oct 2020
Hatzis-Schoch Brent See Remarks
Sold, plan not stated 2×
$133.33K 4,078 at 32.70
57.6%
Sold half or more
5 Oct 2020
Roberts Christopher D. Chief Scientific Officer
Sold, plan not stated 2×
$78.19K 2,500 at 31.28
100%
Sold half or more
1 Oct 2020
Epstein David M. See Remarks
Sold, plan not stated
$363.96K 12,000 at 30.33
1.6%
14 Sep 2020
Hatzis-Schoch Brent See Remarks
Sold, plan not stated 3×
$126.58K 4,078 at 31.04
57.6%
Sold half or more
3 Sep 2020
Roberts Christopher D. Chief Scientific Officer
Sold, plan not stated 2×
$73.99K 2,500 at 29.59
100%
Sold half or more
3 Feb 2020
Hatzis-Schoch Brent See Remarks
Bought
$57.00K 3,000 at 19.00
opened
First buy on file
Showing 1–28 of 28.